



Anaptys Announces Participation in November Investor Conferences

November 4, 2025

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences:

TD Cowen Immunology & Inflammation Summit, Virtual

- Format – Fireside chat
- Date and Time – Wednesday, Nov. 12, 2025 at 8:00am ET

Guggenheim 2nd Annual Healthcare Innovation Conference, Boston, MA

- Format – Fireside chat and 1x1 investor meetings
- Date and Time – Wednesday, Nov. 12, 2025 at 11:30am ET

Stifel 2025 Healthcare Conference, New York, NY

- Format – Fireside chat and 1x1 investor meetings
- Date and Time – Thursday, Nov. 13, 2025 at 1:20pm ET

Jefferies Global Healthcare Conference, London, UK

- Format – Presentation and 1x1 investor meetings
- Date and Time – Monday, Nov. 17, 2025 at 4:00pm GMT

Live webcasts of the fireside chats and presentation will be available on the investor section of the Anaptys website at <https://ir.anaptysbio.com/presentations-and-events>. Replays of the webcasts will be available for at least 30 days following the events.

About Anaptys

Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnlimab, a pathogenic T cell depleter, completed a Phase 2b trial for the treatment of rheumatoid arthritis and is in a Phase 2 trial for the treatment of ulcerative colitis. The company's pipeline also includes ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease with plans to expand development into an additional indication. Additionally, ANB101, a BDCA2 modulator, is in a Phase 1a trial. Anaptys also has discovered and out-licensed in financial collaborations multiple therapeutic antibodies, including a PD-1 antagonist (*Jemperli* (dostarlimab-gxly)) to GSK and an IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals. To learn more, visit www.AnaptysBio.com or follow us on [LinkedIn](#).

Anaptys recently announced the intent to separate its biopharma operations from its substantial royalty assets by year-end 2026, enabling investors to align their investment philosophies and portfolio allocation with the strategic opportunities and financial objectives of each company. Learn more [here](#).

Contact:

Nick Montemarano
Executive Director, Investor Relations
858.732.0178
investors@anaptysbio.com



Source: AnaptysBio, Inc.